Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib

Harmeet K Bhullar; Friyana Bhabha; Chris McCormack; H Miles Prince

doi:10.1111/ajd.14386

Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib

Australas J Dermatol. 2024 Nov 21. doi: 10.1111/ajd.14386. Online ahead of print.

Authors

Harmeet K Bhullar¹, Friyana Bhabha¹, Chris McCormack¹, H Miles Prince²

Affiliations

¹ Sir Peter MacCallum Cancer Centre, Department of Dermatology, Melbourne, Victoria, Australia.
² Sir Peter McCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

PMID: 39570010
DOI: 10.1111/ajd.14386

Abstract

Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.

Keywords: Sneddon Wilkinson disease; acalabrutinib; monoclonal gammopathy of undetermined significance; remission induction; subcorneal pustular dermatoses.